Technology ID
TAB-3643
Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers
E-Numbers
E-245-2020-0
Lead Inventor
Segre, Julia ("Julie") (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Mijares, Lilia (University of Maryland)
Kong, Heidi (NIAMS)
Applications
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Lead IC
NHGRI
ICs
NIAMS
This technology includes a catalog of commensal and pathogenic staphylococci from human skin for utilization as clinical molecular markers of skin conditions and infections. The study of microbial diversity of human skin in both healthy and disease states is important to develop tools to track infections, outbreaks, and multi-drug resistant organisms, particularly in atopic dermatitis, eczema and other microbial-associated infections. Commensal skin S. epidermidis have an open pan-genome and show considerable diversity between isolates.
Commercial Applications
This representative catalog of commensal and pathogenic staphylococci from the skin will also enable quantitative assessments of changes in staphylococcal burden during disease exacerbation, such as chronic relapsing atopic dermatitis or Methicillin-resistant Staphylococcus aureus (MRSA) infection.
Competitive Advantages
Previously unrecognized group of S. epidermidis strains have been characterized, which has the potential to be used as clinical molecular markers.
Licensing Contact: